11/22/2022 8:05:09 AM
Merck Announces Phase 3 KEYNOTE-859 Trial Meets Primary Endpoint In Patients With HER2-Negative Gastric Or GEJ Adenocarcinoma
11/21/2022 6:47:48 AM
Merck To Acquire Imago BioSciences For $36.00/shr In Cash Or Approximate Total Equity Value Of $1.35 Bln
11/8/2022 8:18:09 AM
Portage Biotech Announces Clinical Trial Collaboration Agreement With Merck
11/1/2022 7:17:22 AM
Veeva To Provide Merck With Strategic Pricing Approach And Merck To Have Input Into Veeva's Product Roadmap
10/27/2022 6:47:04 AM
Merck Q3 GAAP EPS From Cont. Opns $1.28; Non-GAAP EPS $1.85
10/24/2022 7:29:06 AM
Merck: EC Approves Expanded Indication For VAXNEUVANCE
10/12/2022 7:15:20 AM
Merck: Health Canada Approves KEYTRUDA As Monotherapy For Adjuvant Treatment Of Adults With Renal Cell Carcinoma
9/27/2022 7:02:33 AM
Merck Animal Health Completes Minority Investment In LeeO Precision Farming
9/22/2022 7:34:15 AM
Merck Animal Health To Acquire Vence; Terms Undisclosed